ATE237337T1 - Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) - Google Patents

Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna)

Info

Publication number: ATE237337T1
Authority: AT; Austria
Prior art keywords: dithio; bis; cisplatin; dimesna; ethanesulfonate
Prior art date: 1994-11-14

Application number

AT95939282T

Other languages

English (en)

Inventor

Frederick Herman Hausheer

Kochat Haridas

Dhanabalan Murali

Dasharatha Gauravaram Reddy

Original Assignee

Bionumerik Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-14

Filing date

1995-11-14

Publication date

2003-05-15

1995-11-14 Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237337T1 publication Critical patent/ATE237337T1/de

Links

239000000203 mixture Substances 0.000 title abstract 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title abstract 2
229960004316 cisplatin Drugs 0.000 title abstract 2
229950009278 dimesna Drugs 0.000 title 1
KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 title 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 title 1
SDNJNDFHCODQDQ-UHFFFAOYSA-N n-(2-ethylphenyl)-2-[[2-[(2-ethylphenyl)carbamoyl]phenyl]disulfanyl]benzamide Chemical compound CCC1=CC=CC=C1NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(=O)NC1=CC=CC=C1CC SDNJNDFHCODQDQ-UHFFFAOYSA-N 0.000 title 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
231100000268 induced nephrotoxicity Toxicity 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT95939282T 1994-11-14 1995-11-14 Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) ATE237337T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/338,379 US5789000A (en)	1994-11-14	1994-11-14	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
PCT/EP1995/004490 WO1996014852A1 (en)	1994-11-14	1995-11-14	Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)

Publications (1)

Publication Number	Publication Date
ATE237337T1 true ATE237337T1 (de)	2003-05-15

Family

ID=23324592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95939282T ATE237337T1 (de)	1994-11-14	1995-11-14	Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna)

Country Status (13)

Country	Link
US (5)	US5789000A (de)
EP (1)	EP0792154B1 (de)
JP (3)	JP4171526B2 (de)
KR (1)	KR100411380B1 (de)
CN (2)	CN101987111A (de)
AT (1)	ATE237337T1 (de)
AU (1)	AU706181B2 (de)
CA (1)	CA2202170C (de)
DE (1)	DE69530412T2 (de)
DK (1)	DK0792154T3 (de)
ES (1)	ES2191717T3 (de)
PT (1)	PT792154E (de)
WO (1)	WO1996014852A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US6025488A (en) *	1994-11-14	2000-02-15	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
PT957920E (pt) *	1996-09-23	2002-06-28	Bionumerik Pharmaceuticals Inc	Reducao dos efeitos toxicos de carboplatina utilizando ditioeteres
US6037336A (en) *	1996-09-23	2000-03-14	Bionumerik Pharmaceuticals, Inc.	Reducing toxic effects of carboplatin using dithioethers
US20070142267A1 (en) *	1998-11-23	2007-06-21	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) *	1998-11-23	2001-11-06	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) *	1998-11-23	2000-01-20	Закрытое акционерное общество "ВАМ"	Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US6197831B1 (en) *	1999-02-09	2001-03-06	Bionumerik Pharmaceuticals, Inc.	Method of treating septic shock
US6034126A (en) *	1999-05-24	2000-03-07	Bionumerik Pharmaceuticals, Inc.	Method for treating glycol poisoning
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6156350A (en) *	1999-12-02	2000-12-05	Corazon Technologies, Inc.	Methods and kits for use in preventing restenosis
US7022315B2 (en)	2000-04-26	2006-04-04	Oregon Health & Science University	Administration of a thiol-based chemoprotectant compound
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
AU2002228772B2 (en) *	2000-11-02	2005-12-08	Sloan Kettering Institute For Cancer Research	Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
US6540733B2 (en) *	2000-12-29	2003-04-01	Corazon Technologies, Inc.	Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
WO2002056755A2 (en) *	2001-01-19	2002-07-25	Bionumerik Pharmaceuticals, Inc.	Method for treating cancer
CA2441228A1 (en) *	2001-03-23	2002-10-03	Aphton Corporation	Combination treatment of pancreatic cancer
US20090191232A1 (en) *	2001-05-04	2009-07-30	Gevas Philip C	Combination therapy for the treatment of tumors
US20030021786A1 (en) *	2001-07-09	2003-01-30	Gevas Philip C.	Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US6352979B1 (en) *	2001-08-20	2002-03-05	Lucinda Lizcano	Method of treating snakebite and complications resulting therefrom
PL370867A1 (en) *	2001-09-24	2005-05-30	Tosk, Inc.	Reduced toxicity cisplatin formulations and methods for using the same
US7176192B2 (en) *	2001-10-26	2007-02-13	Bionumerik Pharmaceuticals, Inc.	Method for treating patients for radiation exposure
US6596320B1 (en) *	2002-01-11	2003-07-22	Bionumerik Pharmaceuticals, Inc.	Method for treating cancer having greater efficacy and reduced adverse effects
JP2006506945A (ja) *	2002-03-28	2006-03-02	メディカル・カレッジ・オブ・オハイオ	遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物
US8710095B2 (en) *	2002-04-30	2014-04-29	Bionumerik Pharmaceuticals, Inc.	Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) *	2002-07-10	2004-01-22	Frederick Hausheer	Formulations and methods of reducing toxicity of anti-infective agents
EP1583540A4 (de) *	2002-12-21	2006-07-26	Bionumerik Pharmaceuticals Inc	Verfahren zur behandlung von toxischen chemischen mitteln ausgesetzten patienten
US7714139B2 (en)	2003-03-27	2010-05-11	Lankenau Institute For Medcial Research	IDO inhibitors and methods of use
US20060020119A1 (en) *	2004-03-29	2006-01-26	Stephen Grimes	Monoclonal antibodies to gastrin hormone
CN100450999C (zh) *	2003-12-17	2009-01-14	比奥纽默里克药物公司	合成二硫化物的方法
US20090111735A1 (en) *	2004-05-12	2009-04-30	Bionumerik Pharmaceuticals, Inc.	Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) *	2004-05-12	2005-11-17	Hausheer Frederick H	Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US7282602B2 (en) *	2004-09-21	2007-10-16	Bionumerik Pharmaceuticals, Inc.	Medicinal disulfide salts
US7235589B2 (en)	2004-09-21	2007-06-26	Bio Numerik Pharmaceuticals, Inc.	Method of treating patients undergoing kidney dialysis
US20060063742A1 (en) *	2004-09-21	2006-03-23	Hausheer Frederick H	Method of treatment for or protection against lymphedema
DK1794586T3 (da)	2004-09-22	2013-05-13	Cancer Advances Inc	Monoklonale antistoffer til progastrin
CN100443081C (zh) *	2005-04-05	2008-12-17	吴一心	木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US20070202077A1 (en) *	2005-12-02	2007-08-30	Brodsky Robert A	Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
CA2648945C (en) *	2005-12-13	2012-04-03	Bionumerik Pharmaceuticals, Inc.	Chemoprotective methods and compositions
WO2007109184A2 (en) *	2006-03-16	2007-09-27	Bionumerik Pharmaceuticals, Inc.	Anti-cancer activity augmentation compounds and formulations and methods of use thereof
WO2008034076A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclosphosphamide in combination with anti-idiotypic vaccines
MX2009008487A (es) *	2007-02-09	2010-01-15	Poniard Pharmaceuticals Inc	Picoplatino encapsulado.
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100310661A1 (en) *	2007-07-16	2010-12-09	Poniard Pharmaceuticals, Inc.	Oral formulations for picoplatin
WO2009039190A1 (en) *	2007-09-17	2009-03-26	Gene Express, Inc.	Cancer risk biomarker
WO2009067699A2 (en) *	2007-11-21	2009-05-28	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) *	2007-11-21	2015-05-05	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
CA2715348A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
JP5667886B2 (ja)	2008-03-14	2015-02-12	バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド	癌患者の生存時間を増大させるための組成物及び化合物の使用方法
US9320760B2 (en) *	2008-03-14	2016-04-26	Bionumerik Pharmaceuticals, Inc.	Compositions and methods of use of compounds to increase cancer patient survival time
CA2717915A1 (en) *	2008-03-14	2009-09-17	Bionumerik Pharmaceuticals, Inc.	Chemoprotective methods and compositions
AU2008352597B2 (en) *	2008-03-14	2012-03-08	Bionumerik Pharmaceuticals, Inc.	Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US20110064828A1 (en) *	2009-09-11	2011-03-17	Novelos Therapeutics, Incorporated	Treatment of metastatic tumors and other conditions
TWI438009B (zh) *	2010-02-19	2014-05-21	Teikoku Pharma Usa Inc	紫杉烷前－乳劑調配物及其製造與使用之方法
US10842770B2 (en)	2010-05-03	2020-11-24	Teikoku Pharma Usa, Inc.	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
EP2804602B1 (de)	2012-01-20	2024-12-04	Del Mar Pharmaceuticals	Verwendung von substituierten hexitolen mit dianhydrogalactitol und analoga zur behandlung von neoplastischen erkrankungen und krebsstammzellen einschliesslich glioblastoma multforme und medulloblastoma
CA2879425A1 (en) *	2012-07-19	2014-01-23	Relypsa, Inc.	Compositions comprising crosslinked cation-binding polymers
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US12150978B2 (en)	2017-06-15	2024-11-26	Cancer Advances Inc.	Compositions and methods for preventing tumors and cancer
EP3624841A4 (de)	2017-06-15	2021-01-27	Cancer Advances, Inc.,	Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2806866C3 (de) *	1978-02-17	1981-02-12	Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld	Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) *	1978-05-30	1982-01-12	Bristol-Myers Company	Pharmaceutical compositions of cisplatin
EP0334083B1 (de) *	1988-03-19	1991-07-24	ASTA Pharma Aktiengesellschaft	Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5227373A (en) *	1991-10-23	1993-07-13	Bristol-Myers Squibb Co.	Lyophilized ifosfamide compositions
JP3954115B2 (ja) *	1992-07-28	2007-08-08	アストラゼネカ・アクチエボラーグ	注射剤および注射剤キット
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

1994
- 1994-11-14 US US08/338,379 patent/US5789000A/en not_active Expired - Lifetime
1995
- 1995-11-03 US US08/553,005 patent/US5902610A/en not_active Expired - Lifetime
- 1995-11-14 CN CN2010102328968A patent/CN101987111A/zh active Pending
- 1995-11-14 EP EP95939282A patent/EP0792154B1/de not_active Expired - Lifetime
- 1995-11-14 DK DK95939282T patent/DK0792154T3/da active
- 1995-11-14 AU AU41168/96A patent/AU706181B2/en not_active Expired
- 1995-11-14 CA CA002202170A patent/CA2202170C/en not_active Expired - Lifetime
- 1995-11-14 WO PCT/EP1995/004490 patent/WO1996014852A1/en not_active Ceased
- 1995-11-14 KR KR1019970703171A patent/KR100411380B1/ko not_active Expired - Lifetime
- 1995-11-14 JP JP51574596A patent/JP4171526B2/ja not_active Expired - Fee Related
- 1995-11-14 ES ES95939282T patent/ES2191717T3/es not_active Expired - Lifetime
- 1995-11-14 PT PT95939282T patent/PT792154E/pt unknown
- 1995-11-14 CN CN951962310A patent/CN1165483B/zh not_active Expired - Lifetime
- 1995-11-14 DE DE69530412T patent/DE69530412T2/de not_active Expired - Lifetime
- 1995-11-14 AT AT95939282T patent/ATE237337T1/de active
1997
- 1997-04-18 US US08/844,544 patent/US5866617A/en not_active Expired - Lifetime
- 1997-04-30 US US08/848,361 patent/US5866615A/en not_active Expired - Lifetime
- 1997-06-18 US US08/878,244 patent/US5866169A/en not_active Expired - Lifetime
2008
- 2008-02-28 JP JP2008047977A patent/JP2008133304A/ja active Pending
2012
- 2012-08-02 JP JP2012172119A patent/JP2012211198A/ja active Pending

Also Published As

Publication number	Publication date
US5789000A (en)	1998-08-04
US5902610A (en)	1999-05-11
PT792154E (pt)	2003-09-30
EP0792154A1 (de)	1997-09-03
MX9703460A (es)	1997-07-31
KR970706830A (ko)	1997-12-01
JPH10509143A (ja)	1998-09-08
CA2202170C (en)	2007-04-10
US5866169A (en)	1999-02-02
DE69530412D1 (de)	2003-05-22
ES2191717T3 (es)	2003-09-16
DK0792154T3 (da)	2003-08-04
KR100411380B1 (ko)	2004-04-30
CN1165483B (zh)	2012-09-05
CN101987111A (zh)	2011-03-23
WO1996014852A1 (en)	1996-05-23
CA2202170A1 (en)	1996-05-23
JP4171526B2 (ja)	2008-10-22
US5866615A (en)	1999-02-02
JP2008133304A (ja)	2008-06-12
AU706181B2 (en)	1999-06-10
EP0792154B1 (de)	2003-04-16
US5866617A (en)	1999-02-02
DE69530412T2 (de)	2003-10-30
CN1165483A (zh)	1997-11-19
JP2012211198A (ja)	2012-11-01
AU4116896A (en)	1996-06-06

Legal Events

Date

Code

Title

Description

2003-10-15

UEP

Publication of translation of european patent specification

Ref document number: 0792154

Country of ref document: EP

Publication	Publication Date	Title
DE69530412D1 (de)	2003-05-22	Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna)
GR3017282T3 (en)	1995-11-30	Novel arylpyridazines, their manufacture, use and medicaments containing them.
ZA91353B (en)	1991-09-25	Pharmaceutical and cosmetic compositions
ATE146674T1 (de)	1997-01-15	Pharmazeutische zusammensetzung zur rektalen verabreichung von wirkstoffen mit topischer medizinischer wirkung im dickdarmniveau
ATE128967T1 (de)	1995-10-15	(poly)sulfid enthaltende polycitraconimide und polyitaconimide.
DE3363270D1 (en)	1986-06-05	Solubilized platinum(ii) complexes
AU4484989A (en)	1990-06-12	Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
GR3003068T3 (en)	1993-02-17	(2,2-bis(aminomethyl)-1,3-propanediol-n,n')platinum complexes
ATE114663T1 (de)	1994-12-15	Ruthenium(iii)-komplexe als antineoplastische mittel.
GB8901881D0 (en)	1989-03-15	Biocidal compositions and treatments
DE69009796D1 (de)	1994-07-21	Biozide Zusammensetzungen und Behandlungen.
DE69940551D1 (de)	2009-04-23	Mercaptane und disulfide
IE820976L (en)	1983-02-21	4'-halo-4'-deoxysucrose derivatives
EP0264953A3 (en)	1988-08-31	Amino acid preparations containing n,n'-bis-l-amino acid-l-cystin peptides for oral and parenteral use
EP0237829A3 (en)	1988-01-07	Tetrahydro-3,4-furandiamine-n-n'-platinum complexes
DE3867086D1 (de)	1992-02-06	Benzothiepino(5,4-c)pyridazin-verbindungen und ihre pharmazeutischen wirkungen.
TR199802270A2 (xx)	1999-05-21	S�lfonamid-ikame etmi� anelize 5-halka-bile�ikleri.
GB9420747D0 (en)	1994-11-30	1,5 benzodiazepine derivatives
DE69506903D1 (de)	1999-02-04	Erhöhte solubiliierung von komplexsalzen von methionin mit zink und mangan durch zusatz von ferriionen
EP0118565A4 (de)	1985-04-03	1,4-methano-2-benzazepin-abkömmlinge.
TR199701605A2 (xx)	1998-07-21	S�lfonamid-substit�e edilmi� bile�ikler
DE69807200D1 (de)	2002-09-19	Inklusionskomplexe in waessriger loesung
NO894505D0 (no)	1989-11-13	Vandig cisplatinloesning.
DK418785D0 (da)	1985-09-16	Vanskeligt antaendelig, biologisk nedbrydelig funktionel vaeske
AU5199286A (en)	1986-06-03	New use of 1,4-dihydropyridine derivatives